Roth Capital Reiterates a Hold Rating on ContraFect

By Carrie Williams

In a report released yesterday, Joseph Pantginis from Roth Capital reiterated a Hold rating on ContraFect (NASDAQ: CFRX), with a price target of $2.20. The company’s shares opened today at $1.85, close to its 52-week low of $1.35.

According to, Pantginis is ranked 0 out of 5 stars with an average return of -12.2% and a 35.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Applied Genetic Technologies, and ImmunoCellular Therapeutics.

ContraFect has an analyst consensus of Moderate Buy.

The company has a one year high of $5.35 and a one year low of $1.35. Currently, ContraFect has an average volume of 82.29K.

ContraFect Corp. is a clinical-stage biotechnology company. It focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. The company scientific and clinical strategy focuses on the use of combination therapies. ContraFect was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.